- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Piramal Pharma Limited — Updates, 05-11-2025: Press Release
05-11-2025 | 09:03 pm
05-11-2025 | 09:03 pm
Piramal Pharma's H1 revenue dropped 5% and EBITDA 38% from CDMO destocking. Net-debt reduced by ₹228 Cr. Management notes Sep/Oct biopharma funding rebound and strong onshore interest. CHG maintained market share, PCH power brands grew 20%. H2 typically outperforms H1.
No comments yet. Be the first to comment!